People: Orthofix International NV (OFIX.OQ)

OFIX.OQ on NASDAQ Stock Exchange Global Select Market

33.58USD
24 Jul 2014
Price Change (% chg)

$-0.58 (-1.70%)
Prev Close
$34.16
Open
$34.07
Day's High
$34.50
Day's Low
$33.51
Volume
28,766
Avg. Vol
52,338
52-wk High
$36.90
52-wk Low
$19.36

Search Stocks

Summary

Name Age Since Current Position

Ronald Matricaria

2014 Independent Chairman of the Board

Bradley Mason

60 2013 President, Chief Executive Officer, Director

Mark Heggestad

55 2014 Chief Financial Officer

Davide Bianchi

49 2013 President - Global Extremity Fixation

Jeffrey Schumm

52 2010 Senior Vice President, General Counsel, Corporate Secretary

Michael Finegan

50 2013 Chief Strategy Officer

James Hinrichs

46 2014 Independent Director

Guy Jordan

65 2013 Independent Director

Anthony Martin

59 2013 Independent Director

Kathleen Regan

52 2014 Independent Director

Maria Sainz

48 2012 Independent Director

Davey Scoon

67 2011 Independent Director

Biographies

Name Description

Ronald Matricaria

Mr. Ronald A. Matricaria is Independent Chairman of the Board of Orthofix International N.V. With more than 35 years of medical device and pharmaceutical experience, Mr. Matricaria served as President and Chief Executive Officer of St. Jude Medical, Inc. and served as Chairman of the Board of Directors. Prior to joining St. Jude Medical, Inc., he was with Eli Lilly and Company where he held multiple executive positions over the course of 23 years. Mr. Matricaria is also currently Chairman of the Board at Volcano Corporation, a member of the Board at Phoenix Children's Hospital and, most recently, served on the Board of Directors of Life Technologies Corporation. Additionally, Mr. Matricaria has served on the board of a number of public and private companies including Home Depot Inc., Diametric Medical Inc., Ceridian Inc., Centocor Inc., Haemonetics Inc., Kinetic Concepts, Inc., Hospira Inc., Cyberonics Inc., Vistacare Inc., Advanced Medical Technology Association (AdvaMed), the Pharmaceutical Manufacturers Association International Section, the American Diabetes Association, the American Foundation for Pharmaceutical Education, the National Foundation for Infectious Diseases, the National Retiree Volunteer Center and the Indiana Repertory Theatre as well as a trustee on the board of the Massachusetts College of Pharmacy and Allied Health Science. He also chaired the BioMedical Engineering Institute campaign, which raised an operating endowment for the Institute at the University of Minnesota. He remains a Trustee emeritus of the University of Minnesota Foundation.

Bradley Mason

Mr. Bradley R. Mason is President, Chief Executive Officer, Director of Orthofix International NV., March 13, 2013. Mr. Mason rejoined Orthofix in March 2013 as our President and Chief Executive Officer after previously serving as Group President, North America from June 2008 through October 2009, and as a Strategic Advisor from November 2009 through October 2010. Prior to being appointed as Group President, North America, he had served as a Vice President of the Company since December 2003, when the Company acquired Breg, Inc. Prior to its acquisition by Orthofix, Mr. Mason had served as President and Chairman of Breg, a company he principally founded in 1989 with five other shareholders. Mr. Mason has over 25 years of experience in the medical device industry, some of which were spent with dj Orthopedics (formally DonJoy) where he was a founder and held the position of Executive Vice President. Since his retirement from Orthofix in 2010, he has served in a variety of part-time consulting and advisory roles, including as a consultant to Orthofix since October 2012 (which consulting relationship has been terminated as of March 13, 2013). Mr. Mason is the named inventor on 38 issued patents in the orthopedic product arena. He graduated Summa Cum Laude with an Associate of Arts and Associate of Science degree from MiraCosta College.

Mark Heggestad

Mr. Mark A. Heggestad is Chief Financial Officer of Orthofix International N.V. Mr. Heggestad has more than 20 years of experience in financial leadership roles in the medical device industry. He most recently served as the Executive Vice President and Chief Financial Officer of American Medical Systems Holdings, Inc., a publicly traded medical technology company focused on pelvic health conditions, from December 2006 until June 2011, when it was acquired by Endo Pharmaceuticals Holdings Inc. From 1987 to 2006, he served in various management positions at Medtronic, Inc., a global leader in medical technologies, including Vice President of Finance and IT for the Cardiac Surgery Business, Vice President of Corporate Audit & Compliance Assurance and Vice President of Corporate Finance, Assistant Controller. Before joining Medtronic Inc., Mr. Heggestad worked from 1982 to 1987 in roles including staff accountant and audit manager at KPMG. He received his Bachelor of Science degree in Accounting from St. Cloud State University.

Davide Bianchi

Mr. Davide Bianchi is President - Global Extremity Fixation of Orthofix International N.V. He was named as the Company’s President, Global Extremity Fixation in December 2013. From February 2009 through June 2013, Mr. Bianchi served as President of the Heart Valve Global Business Unit at Sorin Group. Earlier in his career, he spent ten years with Edwards Lifesciences, where he served as the European Marketing Manager; the Business Director, Emerging Markets; the Managing Director, Germany; the VP, Sales; and, most recently, the VP, Marketing, EMEA. Mr. Bianchi received his M.B.A. from ISTUD Milano.

Jeffrey Schumm

Mr. Jeffrey M. Schumm has been appointed as Senior Vice President, General Counsel, Corporate Secretary of Orthofix International N.V., effective June 20, 2013. Mr. Schumm joined the company as Assistant General Counsel in January 2007, and was promoted to Senior Vice President, General Counsel and Corporate Secretary in October 2010. From 2004 to 2006, Mr. Schumm served as Vice President and General Counsel for Regeneration Technologies, Inc. Earlier in his career, he served as an Assistant Attorney General for the State of Florida, as an associate at Holland & Knight LLP and as a Staff Attorney at the Supreme Court of Florida. Mr. Schumm received his Bachelors of Science in Electrical Engineering and Masters in Business Administration from Lehigh University, and he is a magna cum laude graduate of the Florida State University College of Law.

Michael Finegan

Mr. Michael M. Finegan has been appointed as Chief Strategy Officer of Orthofix International N.V., effective June 20, 2013. Mr. Finegan joined Orthofix in June 2006 as Vice President of Corporate Development, and became the President, Biologics in March 2009. In October 2011, he was promoted to Senior Vice President, Business Development, and President, Biologics. Prior to joining Orthofix, Mr. Finegan spent sixteen years as an executive with Boston Scientific in a number of different operating and strategic roles, most recently as Vice President of Corporate Sales. Earlier in his career, Mr. Finegan held sales and marketing roles with Marion Laboratories and spent three years in banking with First Union Corporation (Wachovia). Mr. Finegan earned a BA in Economics from Wake Forest University.

James Hinrichs

Mr. James F. Hinrichs is Independent Director of Orthofix International N.V. Mr. Hinrichs has served as the Chief Financial Officer of CareFusion Corporation since 2010, where he also has responsibility for corporate development and investor relations activities. He previously served as CareFusion’s Senior Vice President, Global Customer Support, and as its Senior Vice President, Controller. Prior to joining CareFusion when it was spun off from Cardinal Health, Inc., he worked for five years at Cardinal Health in various positions including Executive Vice President and Corporate Controller of Cardinal Health and as Executive Vice President and Chief Financial Officer of its Healthcare Supply Chain Services segment. He joined Cardinal Health following more than a decade of finance and marketing roles at Merck & Co. He holds undergraduate and graduate degrees in business from Carnegie Mellon University.

Guy Jordan

Dr. Guy J. Jordan, Ph.D., is Independent Director of Orthofix International N.V., since December 7, 2004. Most recently, from 1996 to 2002, Dr. Jordan served as a Group President at CR Bard, Inc., a medical device company, where he had strategic and operating responsibilities for Bard’s global oncology business and functional responsibility for all of Bard’s research and development. Dr. Jordan earned a Ph.D. in organic chemistry from Georgetown University as well as an MBA from Fairleigh Dickinson University. He also currently serves on the boards of private health care companies EndoGastric Solutions, Inc., Tangent Medical, Inc. and Catheter Connections, Inc.

Anthony Martin

Dr. Anthony F. Martin, Ph.D., is an Independent Director of Orthofix International N.V. Dr. Martin has more than 25 years of international experience in managing life science businesses in both executive and non-executive roles. Since 2006, he has been the Managing Partner at TMA Consultants, an entity that he founded and that specializes in providing interim management and directorships to biopharmaceutical, life sciences research, medical device and diagnostic companies. He is currently the Non-Executive Chairman of Immunodiagnostics Systems Holdings plc, Sphere Medical Holding plc, and Phico Therapeutics Ltd, and a Non-Executive Director of Abcam plc. He gained a doctorate in Immunology from the University of Manchester Medical School and a first class honors degree in Applied Chemistry from Huddersfield University. Dr. Martin has previously served as chief executive officer at a number of international life sciences and diagnostic businesses including British Bio-Technology Products ltd, Celsis International plc, AZUR Environmental, the molecular biology division of Invitrogen Corporation, and Molecular Probes Inc. He has also previously served as the Chairman of NeuTec Pharma plc and Molecular Insight Pharmaceuticals Inc. and as a board member of Prelude Trust plc and Invitrogen Corporation. In addition, he previously served on the scientific advisory Board of Agilent Technologies.

Kathleen Regan

Ms. Kathleen (“Kathy”) T. Regan is Independent Director of Orthofix International N.V. Kathleen ("Kathy") T. Regan has been advising and investing in healthcare companies for the past twenty-five years. She became a venture partner of Radius Venture, a venture capital firm focused on the life sciences and healthcare industry, in 2010. Prior to joining Radius, Ms. Regan was the Executive Vice President of Keystone Dental, Inc., a portfolio company of Warburg Pincus LLC, where she led strategy and business development. Between 2003 and 2008, she served as a consultant to Warburg Pincus LLC, a leading global private equity firm, where she was involved in investing with the medical technology team and served as a board member to several portfolio companies. Previously, Ms. Regan spent fifteen years in healthcare investment banking and was a Senior Managing Director and Director of Healthcare Investment Banking at Sun Trust Robinson Humphrey LLC and, previously, a Managing Director at Freedom Securities Tucker Anthony. Ms. Regan currently serves on the Board of Trustees of the Lutheran HealthCare, a not for profit hospital, family health network, long term care and home health care system in New York. Ms. Regan received a B.A., cum laude, from Princeton University and a MPH from Columbia University.

Maria Sainz

Ms. Maria Degois Sainz is an Independent Director of Orthofix International N.V. She became a director of Orthofix in November 2012, after previously having served on our Board from June 2008 to September 2011. In May 2012, she became the President and Chief Executive Officer, and a director, of CardioKinetix Inc., a heart-related medical device company. From April 2008 to October 2011, she was President and Chief Executive Officer of Concentric Medical, Inc., a company developing and commercializing devices to perform mechanical clot removal post-stroke, which was sold to Stryker Corporate in October 2011. Upon this acquisition, she served as General Manager of the Stryker Neurovascular business unit until April 2012. From 2003 to 2006, she was the President of the Cardiac Surgery division of Guidant Corporation. After Boston Scientific acquired Guidant, Ms. Sainz led the integration process for both the Cardiac Surgery and European Cardiac Rhythm Management business of Guidant into Boston Scientific. Between 2001 and 2003, Ms. Sainz was the Vice President of Global Marketing – Vascular Intervention of Guidant. Ms. Sainz earned a Bachelor and Masters of Arts from the Universidad Complutense de Madrid and a Master’s Degree in International Management from American Graduate School of International Management. Ms. Sainz became a director of The Spectranetics Corporation, a publicly-traded medical device company, in November 2010.

Davey Scoon

Mr. Davey S. Scoon, CPA., is Independent Director of Orthofix International N.V., since August 16, 2011. Mr. Scoon serves as Chairman of the Board of Directors of Tufts Health Plan, where he has been a director since 1981. He also serves as Chairman of the Board of Trustees of Allianz Funds, a registered investment company consisting of 22 mutual funds, where he has been a director since 2006. Mr. Scoon is the Chairman of the Audit Committee of pharmaceutical companies AMAG Pharmaceuticals, Inc. and Biodel Inc., where he has been a director since 2006 and 2012, respectively. He has been an Adjunct Assistant Professor at Tufts University School of Medicine since 2005. He also previously served as the Chairman of the Audit Committee of pharmaceutical companies NitroMed, Inc. and CardioKine, Inc., where he was a director from 2003 to 2009 and 2005 to 2012, respectively. He was also a member of the Board of Directors of Inotek Pharmaceuticals Corporation, a pharmaceutical company, from 2006 to 2009. From 2003 to 2005, Mr. Scoon was Chief Administrative and Financial Officer of Tom’s of Maine, a company that manufactures natural care products. From 2001 to 2003, Mr. Scoon served as Chief Financial and Administrative Officer for Sun Life Financial U.S., and from 1999 to 2001, Mr. Scoon served as Vice President and Chief Financial Officer for Sun Life Financial U.S. From 1985 to 1999, Mr. Scoon was employed by Liberty Funds Group of Boston (formerly Colonial Management) in various capacities, including Chief Financial Officer and Chief Operating Officer. Mr. Scoon holds a B.B.A. from the University of Wisconsin and an M.B.A. from Harvard Business School. He is a lecturer at the University of Wisconsin-Madison.

Basic Compensation

Name Fiscal Year Total

Ronald Matricaria

--

Bradley Mason

3,013,200

Mark Heggestad

--

Davide Bianchi

892,787

Jeffrey Schumm

1,038,360

Michael Finegan

1,043,370

James Hinrichs

--

Guy Jordan

--

Anthony Martin

--

Kathleen Regan

--

Maria Sainz

--

Davey Scoon

--
As Of 30 Dec 2013

Options Compensation

Search Stocks